AstraZeneca and Nektar Therapeutics have entered into an agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation,
DOR BioPharma has announced that it has been awarded an approximate $9.4m grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National
Impax Pharmaceuticals has reported the positive results from a recently completed phase II trial of its late-stage Parkinson’s disease drug candidate IPX066. In the cross-over trial, IPX066 reduced
Provectus Pharmaceuticals has completed the treatment portion, including all protocol-allowed retreatments of all patients, of phase 2 clinical trial of PV-10 for metastatic melanoma. PV-10 is a injectable
Enzo Biochem has entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human
Neuralstem has revealed that the FDA has approved its Investigational New Drug (IND) application to commence a phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou
Celsion has announced that the Data Safety Monitoring Board (DSMB) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox phase III
King Pharmaceuticals has announced the commercial availability for EMBEDA (morphine sulfate and naltrexone hydrochloride) extended release capsules, a long-acting Schedule II opioid analgesic for the management of moderate
Incyte has announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. The results were obtained from a multi-center
Lorus Therapeutics has published data from study of its novel anti cancer therapy, conducted by its research team. In the study, data was presented from the preclinical evaluation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.